Alentis Therapeutics AG Secures $181.4 Million for Groundbreaking CLDN1 Cancer and Fibrosis Treatments

Alentis Therapeutics AG is excited to announce the successful completion of a $181.4 million funding round, enabling the company to accelerate its groundbreaking research and development efforts. As a clinical stage biotechnology firm focused on pioneering therapies targeting Claudin-1 (CLDN1), Alentis is on a mission to develop first-in-class antibodies and antibody-drug conjugates (ADCs) to combat CLDN1+ tumors and organ fibrosis. The recent investment will be key in advancing Alentis' innovative portfolio, particularly its lead oncology asset, ALE.C04, which uniquely addresses the tumor microenvironment (TME) to enhance anti-cancer activity—an approach that has the potential to redefine treatment paradigms for solid tumors. Additionally, the funding will support the ongoing Phase 1 clinical trials of ALE.F02, aimed at reversing advanced organ fibrosis by targeting the pathological overexpression of CLDN1. Established in 2019 based on cutting-edge research from Prof. Thomas Baumert at the University of Strasbourg, Alentis is uniquely equipped to transform the landscape of cancer and fibrosis therapies, being the only company focusing on this critical target. Headquartered in the vibrant pharma-biotech hub of Basel, Switzerland, with a dedicated R&D center in Strasbourg, Alentis is committed to delivering innovative treatments that aim to improve the lives of patients suffering from these debilitating conditions. This funding marks a significant milestone in Alentis' journey, propelling us closer to achieving our vision of a healthier future through targeted therapies. For further information, please visit our website at www.alentis.ch or reach out to us at info@alentis.ch.